This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...
Scientists warn against new risks of Ozempic and other popular weight loss drugs
The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...